Auven Therapeutics Announces AstraZenecaโ€™s MedImmune Acquires Antibody-Drug Conjugate Company Spirogen and Invests in _

Monday, October 14, 2013
LAUSANNE, Switzerland & LONDON & ST THOMAS, U.S. Virgin Islands & NEW YORK--(BUSINESS WIRE)--Auven Therapeutics today announced that its strategic investment in the ADC field has been validated by the sale of its platform technology portfolio Company Spirogen to AstraZenecaโ€™s MedImmune.

 

This post is a mere snippet of world-wide industry news, sponsored by:
BizLocal.com
BizLocal is a web-property of Inspetta LLC, providing innovative web, software and marketing services to business.  Call 800-785-2925 for more information.


Comments

Only registered users can leave comments.
Comment text:

DB44 MLM Software by Inspetta